Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yi-Mi Wu

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012Maha Hussain, Stephanie Daignault-Newton, Przemyslaw W Twardowski, et al.
Cancer Research|December 14, 2017
Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance MechanismsCostanza Paoletti, Andi K Cani, Jose M Larios, et al.
Nature|June 23, 2012
The mutational landscape of lethal castration-resistant prostate cancerCatherine S Grasso, Yi-Mi Wu, Dan R Robinson, et al.
Science Translational Medicine|December 3, 2011
Personalized oncology through integrative high-throughput sequencing: a pilot studySameek Roychowdhury, Matthew K Iyer, Dan R Robinson, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean Ching-Yi Tien, Yu Chang, Yuping Zhang, et al.
JAMA Oncology|February 25, 2021
Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid TumorsErin F Cobain, Yi-Mi Wu, Pankaj Vats, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2020
Targeting transcriptional regulation of SARS-CoV-2 entry factors <i>ACE2</i> and <i>TMPRSS2</i>Yuanyuan Qiao, Xiao-Ming Wang, Rahul Mannan, et al.
Cell Reports. Medicine|October 5, 2024
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean Ching-Yi Tien, Jie Luo, Yu Chang, et al.
Nature|August 8, 2017
Integrative clinical genomics of metastatic cancerDan R Robinson, Yi-Mi Wu, Robert J Lonigro, et al.
JAMA|September 2, 2015
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in YouthRajen J Mody, Yi-Mi Wu, Robert J Lonigro, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012Maha Hussain, Stephanie Daignault-Newton, Przemyslaw W Twardowski, et al.
Cancer Research|December 14, 2017
Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance MechanismsCostanza Paoletti, Andi K Cani, Jose M Larios, et al.
Nature|June 23, 2012
The mutational landscape of lethal castration-resistant prostate cancerCatherine S Grasso, Yi-Mi Wu, Dan R Robinson, et al.
Science Translational Medicine|December 3, 2011
Personalized oncology through integrative high-throughput sequencing: a pilot studySameek Roychowdhury, Matthew K Iyer, Dan R Robinson, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean Ching-Yi Tien, Yu Chang, Yuping Zhang, et al.
JAMA Oncology|February 25, 2021
Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid TumorsErin F Cobain, Yi-Mi Wu, Pankaj Vats, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2020
Targeting transcriptional regulation of SARS-CoV-2 entry factors <i>ACE2</i> and <i>TMPRSS2</i>Yuanyuan Qiao, Xiao-Ming Wang, Rahul Mannan, et al.
Cell Reports. Medicine|October 5, 2024
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean Ching-Yi Tien, Jie Luo, Yu Chang, et al.
Nature|August 8, 2017
Integrative clinical genomics of metastatic cancerDan R Robinson, Yi-Mi Wu, Robert J Lonigro, et al.
JAMA|September 2, 2015
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in YouthRajen J Mody, Yi-Mi Wu, Robert J Lonigro, et al.
Pageof 8